BioCentury
ARTICLE | Clinical News

FDA accepts Regeneron's sBLA for 12-week Eylea dosing

December 15, 2017 4:08 AM UTC

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) said FDA accepted an sBLA for a quarterly dosing schedule of Eylea aflibercept to treat wet age-related macular degeneration (AMD). Its PDUFA date is Aug. 11, 2018. The drug is already approved in the indication under an eight-week dosing schedule...